Diligence memo · auto-generated · as of July 2, 2026
Vyripharm Enterprises, Inc.
Vyripharm Enterprises, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Vyripharm Enterprises, Inc. operates in Pharmaceuticals, based in HOUSTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vyripharm Enterprises, Inc. has raised $300M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $300M on 2021-10-13.
Most recent recorded round closed around 2021-10-13.
Valuation (modeled)modeled
Provath models Vyripharm Enterprises, Inc. at approximately $7.2B (range $1.4B–$13.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.95× the median modeled value of Series D+ Pharmaceuticals companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.7 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 98% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Nuvation Bio Inc., Recursion Pharmaceuticals, Inc., Verona Pharma plc, Cingulate Inc., Day One Biopharmaceuticals Holding Co LLC.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.